EGFR and non-small cell lung carcinoma: This confirms a recent single-cell study’s finding that the PC-9 non-small cell lung carcinoma line, which harbors an activating EGFR mutation, develops a cellular state resistant to EGFR inhibitors through expression of EMT markers as well as accumulation of 1-methylnicotinamide48.